Acute use of teriparatide and palopegteriparatide in the management of hungry bone syndrome following parathyroidectomy

Hypocalcemia remains a major risk of head and neck surgery, especially after parathyroidectomy for treatment of hyperparathyroidism. In this case, we present a patient with hyperparathyroidism who developed hungry bone syndrome postoperatively, requiring more than 15 grams of calcium supplementation per day but who only sustained normal calcium levels with the addition of teriparatide followed by palopegteriparatide. This is 1 of only a few case reports in the literature describing acute use of teriparatide or palopegteriparatide in the management of severe hungry bone syndrome.